Enhancing Sleep Quantity and Quality with a Novel GABAergic Dietary Supplement
Authors: Bernsley Devon , Sahin Kazim , Kilic Ertugrul , Korkusuz Ahmet Kayhan , Orhan Cemal , Aldatmaz İsmail Ertuğ , Er Besir 
Published: May 2024

Purpose: The primary objective of this investigation was to evaluate the effects of BH_SLP_01 (Bonafide Health Sleep Product) on sleep quality and brain wave patterns using a caffeine-induced insomnia model, and on sleep duration and latency using a pentobarbital-induced sleep model. Methods: Five male BALB/c mice were allocated per treatment arm (age: 8 weeks, body mass: 180 ± 20 g). Treatment arms included control, caffeine or phenobarbital (active) control, and BH_SLP_01. Caffeine treatment model. To induce sleep disturbance, 7.5 mg/kg caffeine was injected intraperitoneally at the 15th minute (min) of recordings, and second injections (saline or combinations) were performed at the 30th minute. Brain electrical activity was monitored and recorded for a total of two hours using electrocorticography (ECoG) recording. Serum melatonin, serotonin, and dopamine were measured by ELISA. Brain levels of MDA were measured by HPLC, and protein concentrations were determined using Western Blot analysis. Phenobarbital treatment model Groups were administered saline or BH_SLP_01, and then, 45 min later, pentobarbital (42 mg/kg) was injected. After injection, sleep latency and duration were measured. Study treatments were compared using an ANOVA and Student's unpaired t-test. Significance levels were set at p<0.05. Results: Analysis of ECoG recording data revealed notable findings. In the caffeine-pretreated group, a significant increase in amplitude was observed during the 30-45 min interval, compared to control. Caffeine administration also significantly increased frequency at 75-90 and 90-105 min compared to control (p<0.05). Conversely, the group treated with BH_SLP_01 displayed no significant changes in amplitude and frequency, except for a significant change in frequency at 90-105 min compared to control (p<0.05). Both sleep duration and sleep latency were significantly improved for BH_SLP_01 compared to control and phenobarbital control (p<0.05). In addition, serotonin, dopamine, melatonin, GABAA R2, GABAB R1, GABAB R2, 5-HT1A, GluA1, GluN1, GluN2A, Bax, Bcl-2, and Caspase-3 levels were significantly improved by BH_SLP_01 compared to control and caffeine control (p<0.05). Conclusion: The results of these studies provide evidence for the effcacy of BH_SLP_01 to improve impaired sleep, leading to notable enhancements in markers of deep sleep. This conclusion is supported by the significant upregulation of GABA, glutamine receptors, and endogenous melatonin, all of which collectively contribute to the augmentation of both sleep quantity and quality. These findings underscore the potential of BH_SLP_01 as a promising therapeutic intervention for optimizing sleep parameters and promoting overall sleep wellness.

This research was supported by Bonafide Health, LLC.

This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.